In this study, subjects were randomized to either nicotine replacement patches or ENDs device which used e ENDS devices using e-nicotine liquid cartridges. In order to maintain the blind, subjects used both the nicotine replacement patches and the ENDS devicedevices. Subjects were requested not to smoke, but the number of regular cigarettes used were collected. Subject were seen every day for 15 days. The nicotine patch was applied, at rotating sites, and the ENDS nicotine cartridge was replaced every day. The cartridge was weight weighed when dispended dispensed and upon return. On days, 1, 5, and 10 subjects remained in the clinic for 4 hours for collection of biomarkers. On these days, a new ENDS nicotine cartridge device was inserted and then used for 10 puffs were taken over 10 minutes, and then not used for 4 hoursthe remaining collection period. A new cartridge was insert inserted at the end of the 4 hours. The -hour collection period. A nicotine replacement patch was applied prior to using the ENDS device on these days.
...
In this study, the weight of the contents in the cartridges were cartridge was tracked. A Product Accountability (The DA ) domain was submitted used to represent dispensed and returned weights of each cartridge. Only a few rows are shown. The produt accountability product accountability information was not provided for the nicotine replaement patches replacement patches.
Dataset wrap |
---|
Dataset2 |
---|
Row | STUDYID | DOMAIN | USUBJID | DASEQ | DAREFID | DATESTCD | DATEST | DACAT | DASCAT | DAORRES | DAORRESU | DASTRESC | DASTRESN | DASTRESU | VISITNUM | DADTC |
---|
1 | TEDP07 | DA | 10001 10001 | | CRT8754 | DISPAMT | Dispensed Amount | STUDY PRODUCT | E-LIQUID | 25.3 | g | 25 | 25 | g | 1 | 2004-06-06 | 2 | TEDP07 | DA | 10001 10001 | | CRT8755CRT8754 | RETAMT | Returned Amount | STUDY PRODUCT | E-LIQUID | 23 | g | 23 | 23 | g | 1 | 2020-06-06 | 3 | TEDP07 | DA | 10001 10001 | | CRT9756 | DISPAMT | Dispensed Amount | STUDY PRODUCT | E-LIQUID | 25.1 | g | 25 | 25 | g | 1 | 2020-06-07 | 4 | TEDP07 | DA | 10001 10001 | | CRT9757CRT9756 | RETAMT | Returned Amount | STUDY PRODUCT | E-LIQUID | 10 | g | 14 | 14314 | g | 2 | 2020-06-08 | 5 | TEDP07 | DA | 10001 10001 | | CRT8755CRT9955 | DISPAMT | Dispensed Amount | STUDY PRODUCT | E-LIQUID | 25.2 | g | 25 | 25 | g | 2 | 2004-06-0908 |
|
|
EC was used to represent the collected exposure data since a double dummy -blind design was used. ,while the The EX domain was used to represent the subject's exposure to the actual product containing nicotine. The sponsor applicant represented each cartridge and patch used. The dose was represented has as "1" to indicate only one cartidge wsa used1 cartridge or patch. The actual actual date and specific time of usage of the cartridge was recorded precisely on days 1, 5, and 10, while only the date of usage was reccorded recorded on other days.
Dataset wrap |
---|
|
Dataset2 |
---|
Row | STUDYID | DOMAIN | USUBJID | ECSEQ | ECTRT | ECDOSE | ECDOSTXT | ECDOSU | ECDOSFRM | ECROUTE |
---|
ECFREQ | ECLOC | ECLAT | ECDIR | EPOCH | ECSTDTC | ECENDTC |
---|
1 | TEDP07 | EC | 10001 | 1 | ENDS |
---|
1INHALEDRESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | 2020-06-01T08:00 | 2020-06-01T08:10 | 2 | TEDP07 | EC | 10001 | 2 | PATCH | 1 |
| PATCH | PATCH | TRANSDERMAL | ARM | RIGHT | UPPER | PRODUCT EXPOSURE | 2020-06-01 | 2020-06-02 |
---|
3 | TEDP07 | EC | 10001 | 3 | ENDS |
| AD LIBITUM |
---|
1INHALED | AD LIBITUM | RESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | 2020-06-01T12:10 | 2020-06-02 | 4 | TEDP07 | EC | 10001 |
---|
11INHALED | AD LIBITUM | RESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | 2020-06-02 | 2020-06- | 0215 | PATCH | 1 |
| PATCH | PATCH | TRANSDERMAL | ARM | LEFT | UPPER | PRODUCT EXPOSURE | 2020-06-02 | 2020-06-03 | 6 | TEDP07 | EC | 10001 |
---|
21INHALED | AD LIBITUM | RESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | 2020-06-03 | 2020-06- | 0337 | PATCH | 1 |
| PATCH | PATCH | TRANSDERMAL | LEG | LEFT | UPPER | PRODUCT EXPOSURE | 2020-06-03 | 2020-06-04 | 7 | TEDP07 | EC | 10001 |
---|
41INHALED | AD LIBITUMRESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | 2020-06-04 | 2020-06-05 | 8 | TEDP07 | EC | 10001 |
---|
59 | PATCH | 1 |
| PATCH | PATCH | TRANSDERMAL | LEG | LEFT | LOWER | PRODUCT EXPOSURE | 2020-06-04 | 2020-06-05 | 9 | TEDP07 | EC | 10001 |
---|
61INHALED | ONCERESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | 2020-06- | 09T809T8711 | PATCH | 1 |
| PATCH | PATCH | TRANSDERMAL | LEG | RIGHT | LOWER | PRODUCT EXPOSURE | 2020-06-10 | 2020-06-11 | 11 | TEDP07 | EC | 10001 |
---|
81INHALED | AD LIBITUMRESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | 2020-06-10T12:40 | 2020-06-11 |
|
|
Subject 10001 was randomized to the 5% pharmaceutical strength of the nicotine e-liquid, and subject 20001 was randomized to the nicotine patch with a pharmaceutical strength of 14mg. The applicant only represented the active product exposure for each subject in EX.
Dataset wrap |
---|
|
Dataset2 |
---|
Row | STUDYID | DOMAIN | USUBJID | EXSEQ | EXTRT | EXDOSE | EXDOSU | EXDOSFRM | EXROUTE |
---|
EXFREQ | EXLOC | EXLAT | EXDIR | EPOCH | EXPSTRG | EXPSTRGU |
---|
ECSTDTCECENDTCEXENDTC |
---|
1 | TEDP07 | EX | 10001 | 1 | e nicotine liquid |
---|
3INHALED | ONCE | TREATMENTCARTRIDGE | RESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | 5 | % | 2020-06-01T08:00 | 2020-06-01T:8:10 | 2 | TEDP07 | EX | 10001 | 2 | e nicotine liquid | 15.1 | g |
---|
INHALED | AD LIBITUM | TRE5ATMENTCARTRIDGE | RESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | 5 | % | 2020-06- | 01T0801T12:10 | 2020-06-02 | 3 | TEDP07 | EX | 10001 | 3 | e nicotine liquid | 13 | g |
---|
INHALED | AD LIBITUM | CARTRIDGE | RESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | TREATMENT0203 | 4 | TEDP07 | EX | 10001 | 4 | e nicotine liquid | 12 | g |
---|
INHALED | AD LIBITUM | CARTRIDGE | RESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | TREATMENT0304 | 5 | TEDP07 | EX | 10001 | 5 | e nicotine liquid | 9 | g |
---|
INHALED | AD LIBITUM | CARTRIDGE | RESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | TREATMENT | 5 | % | 2020-06-04 | 2020-06-05 | 6 | TEDP07 | EX | 10001 | 6 | e nicotine liquid | 7 | g |
---|
INHALED | ONCE | CARTRIDGE | RESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | TREATMENT09T0809T0810T08:40 | 7 | TEDP07 | EX | 10001 | 7 | e nicotine liquid | 5 |
---|
mgINHALED | AD LIBITUM | CARTRIDGE | RESPIRATORY (INHALATION) |
|
|
| PRODUCT EXPOSURE | TREATMENT | 5 | % | 2020-06-10T12:40 | 2020-06-11 | 8 | TEDP07 | EX | 20001 | 1 | nicotine replacement therapy | 1 | PATCH | PATCH | TRANSDERMAL |
---|
QD | TREATMENTPRODUCT EXPOSURE | 14 | mg | 2020-06-01 | 2020-06-02 | 9 | TEDP07 | EX | 20001 | 2 | nicotine replacement therapy | 1 | PATCH | PATCH | TRANSDERMAL |
---|
QD | TREATMENTPRODUCT EXPOSURE | 14 | mg | 2020-06-02 | 2020-06-03 | 10 | TEDP07 | EX | 20001 | 3 | nicotine replacement therapy | 1 | PATCH | PATCH | TRANSDERMAL |
---|
QD | TREATMENTPRODUCT EXPOSURE | 14 | mg | 2020-06-03 | 2020-06-04 | 11 | TEDP07 | EX | 20001 | 4 | nicotine replacement therapy | 1 | PATCH | PATCH | TRANSDERMAL |
---|
QDTREATMENTPRODUCT EXPOSURE | 14 | mg | 2020-06-04 | 2020-06-05 | 12 | TEDP07 | EX | 20001 | 5 | nicotine replacement therapy | 1 | PATCH | PATCH | TRANSDERMAL |
---|
QDTREATMENTPRODUCT EXPOSURE | 14 | mg | 2020-06-10 | 2020-06-11 |
|
|